Scientific work

Doç. Dr. Dilek Erdem

90 publications. The source of the information is stated next to each publication.

Back to profile

  1. Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma

    Immunotherapy, 2026

    DOI 10.1080/1750743x.2026.2722548 PMID 42683510 Open-access full textSource: OpenAlex

  2. Abstract PS5-02-08: Impact of Prior T-DM1 Exposure on the Efficacy of Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps5-02-08 Source: OpenAlex

  3. Abstract PS5-05-14: Real-world outcomes of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps5-05-14 Source: OpenAlex

  4. Lung Metastatic Ameloblastoma: A Hidden Cause of Pulmonary Nodules

    Balkan medical journal, 2026

    DOI 10.4274/balkanmedj.galenos.2025.2025-8-6 PMID 40936298 Open-access full textSource: Europe PMC

  5. Abstract PS4-04-11: Statins enhance trastuzumab deruxtecan efficacy: Preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps4-04-11 Source: OpenAlex

  6. First-in-class HIF-2α therapy in genitourinary oncology: Belzutifan from von Hippel–Lindau disease to advanced renal cell carcinoma

    Cancer Chemotherapy and Pharmacology, 2026

    DOI 10.1007/s00280-025-04861-x PMID 41569310 2 citations (OpenAlex) Source: OpenAlex

  7. Efficacy and toxicity outcomes of total neoadjuvant FLOT versus perioperative FLOT in resectable gastric cancer: Results from the Turkish Oncology Gastrointestinal Cancer Working Group.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.2_suppl.414 Source: OpenAlex

  8. Clinical outcomes of adjuvant treatment strategies in locally advanced gastroesophageal and gastric adenocarcinoma with poor pathological response to neoadjuvant FLOT: A Turkish Oncology Group (TOG) study.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.e16150 Open-access full textSource: OpenAlex

  9. Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70213 PMID 41147655 3 citations (Europe PMC) Source: OpenAlex

  10. Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program

    Future Oncology, 2025

    DOI 10.1080/14796694.2025.2570637 PMID 41103123 Open-access full textSource: OpenAlex

  11. Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-15287-2 PMID 41275151 Open-access full textSource: OpenAlex

  12. HER2 POZITIF METASTATIK MEME KANSERLI HASTALARDA TRASTUZUMAB DERUXTECAN’IN GERÇEK YAŞAM VERILERI: TÜRK ONKOLOJI GRUBU ÇOK MERKEZLI ÇALIŞMASI

    Kocaeli Üniversitesi - AVESİS, 2025

    Source: OpenAlex

  13. ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer

    New England Journal of Medicine, 2025

    DOI 10.1056/nejmoa2511885 PMID 41124204 199 citations (OpenAlex) Source: OpenAlex

  14. 169P: THASSOS-INTL Türkiye subset: Unveiling treatment patterns and clinical outcomes in resectable early-stage NSCLC

    Journal of Thoracic Oncology, 2025

    DOI 10.1016/s1556-0864(25)00363-6 Open-access full textSource: OpenAlex

  15. Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma?

    Current Oncology, 2024

    DOI 10.3390/curroncol31090384 PMID 39330012 Open-access full textSource: OpenAlex

  16. Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study

    Cancers, 2024

    DOI 10.3390/cancers16122251 PMID 38927957 4 citations (Europe PMC) Open-access full textSource: OpenAlex

  17. Association Between Baseline and Changes in Early Neutrophil-to-Lymphocyte Ratio on Survival in Patients with Metastatic Bladder Carcinoma Treated with Immunotherapy

    Medicina, 2024

    DOI 10.3390/medicina60122103 PMID 39768982 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  18. Immune Checkpoint Blockade Therapies Efficacy and Toxicity in Patients With Impaired Renal Function in Metastatic Bladder Cancer

    Clinical Genitourinary Cancer, 2024

    DOI 10.1016/j.clgc.2024.102228 PMID 39461025 1 citation (Europe PMC) Open-access full textSource: ORCID

  19. Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors

    Clinical Genitourinary Cancer, 2024

    DOI 10.1016/j.clgc.2024.102163 PMID 39126823 1 citation (Europe PMC) Source: ORCID

  20. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.24.01001 PMID 38857463 139 citations (OpenAlex) Open-access full textSource: ORCID

  21. Immune checkpoints blockade therapies' efficacy and toxicity in patients with impaired renal function in metastatic bladder cancer.

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.4_suppl.594 Open-access full textSource: OpenAlex

  22. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

    BMC Cancer, 2023

    DOI 10.1186/s12885-023-10609-8 PMID 36765293 18 citations (Europe PMC) Open-access full textSource: OpenAlex

  23. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study

    Journal of Cancer Research and Clinical Oncology, 2023

    DOI 10.1007/s00432-023-04766-3 PMID 37067546 7 citations (Europe PMC) Open-access full textSource: OpenAlex

  24. Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study

    Neoplasma, 2023

    DOI 10.4149/neo_2022_221004n984 PMID 36620878 Open-access full textSource: OpenAlex

  25. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

    Acta Oncologica, 2023

    DOI 10.1080/0284186x.2023.2202330 PMID 37083566 3 citations (Europe PMC) Open-access full textSource: OpenAlex

  26. Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice

    Clinical Genitourinary Cancer, 2023

    DOI 10.1016/j.clgc.2022.11.019 PMID 36641357 2 citations (Europe PMC) Source: ORCID

  27. Comparison of objective response rate and long-term overall survival in patients with treated immune checkpoint inhibitors in metastatic urothelial carcinoma.

    Journal of Clinical Oncology, 2023

    DOI 10.1200/jco.2023.41.6_suppl.481 Source: OpenAlex

  28. The Prognostic Significance of Lymphocyte-C-Reactive Protein Ratio in Non-Small Cell Lung Cancer Patien Receiving Immunotherapy

    Eurasian Journal of Medical Investigation, 2023

    DOI 10.14744/ejmi.2023.47013 Source: OpenAlex

  29. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-03984-5 PMID 35381885 3 citations (Europe PMC) Open-access full textSource: OpenAlex

  30. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer

    Journal of Cancer Research and Therapeutics, 2022

    DOI 10.4103/jcrt.jcrt_1104_21 PMID 36510987 6 citations (Europe PMC) Open-access full textSource: OpenAlex

  31. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-04252-2 PMID 36048274 5 citations (Europe PMC) Open-access full textSource: OpenAlex

  32. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

    Future Oncology, 2022

    DOI 10.2217/fon-2022-0083 PMID 35734870 3 citations (Europe PMC) Open-access full textSource: OpenAlex

  33. Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study

    Journal of Chemotherapy, 2022

    DOI 10.1080/1120009x.2022.2073159 PMID 35579894 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  34. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-04087-x PMID 35689097 11 citations (Europe PMC) Open-access full textSource: OpenAlex

  35. Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.2022.40.16_suppl.e12610 2 citations (OpenAlex) Source: OpenAlex

  36. Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

    Bursa Uludag University - AVESIS, 2022

    Source: OpenAlex

  37. Discoidin domain receptor 1 as a promising biomarker for high-grade gliomas

    Journal of Cancer Research and Therapeutics, 2022

    DOI 10.4103/jcrt.jcrt_708_21 PMID 37147958 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  38. Diffusion-Weighted Imaging of Brain Metastasis: Correlation of MRI Parameters with Histologic Type

    Turkish neurosurgery, 2022

    DOI 10.5137/1019-5149.jtn.32084-20.4 PMID 34542898 10 citations (Europe PMC) Open-access full textSource: ORCID

  39. Effects of Cytoreductive Nephrectomy on Nivolumab Outcomes in Patients with Metastatic Clear Cell Renal Carcinoma: A Retrospective Observational Real-Life Data of Turkish Oncology Group

    Research Square, 2022

    DOI 10.21203/rs.3.rs-1693977/v1 Open-access full textSource: ORCID

  40. Impact of corona-phobia on attitudes and acceptance towards COVID-19 vaccine among cancer patients: a single-center study

    Future oncology (London, England), 2022

    DOI 10.2217/fon-2021-1015 PMID 34851155 13 citations (Europe PMC) Open-access full textSource: ORCID

  41. The Percentage of ALK-Positive Cells and the Efficacy of First-Line Alectinib in Advanced Non-small Cell Lung Cancer Is it a novel factor for stratification? (Turkish Oncology Group Study)

    Research Square, 2022

    DOI 10.21203/rs.3.rs-1583429/v1 Open-access full textSource: ORCID

  42. 124P Talazoparib in locally advanced or metastatic breast cancer patients: Experience from an early access program in Turkey

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.03.138 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  43. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study

    Cancer Investigation, 2021

    DOI 10.1080/07357907.2021.2017952 PMID 34894960 3 citations (Europe PMC) Source: OpenAlex

  44. Metastatic cutaneous melanoma epidemiological registry in Turkey: A preliminary evaluation of diagnosis and treatment approaches

    Sakarya Üniversitesi Kurumsal Açık Akademik Arşivi, 2021

    Source: OpenAlex

  45. Metastatic cutaneous melanoma epidemiological registry in Turkey: A preliminary evaluation of diagnosis and treatment approaches

    Bursa Uludag University - AVESIS, 2021

    Source: OpenAlex

  46. Ixabepilone in metastatic breast cancer: Real-world experience

    Journal of Oncological Science, 2021

    DOI 10.37047/jos.2021-81340 3 citations (OpenAlex) Open-access full textSource: ORCID

  47. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab

    International Journal of Clinical Oncology, 2021

    DOI 10.1007/s10147-021-01936-6 PMID 34023933 14 citations (Europe PMC) Source: ORCID

  48. Real Life Experience of Patients With Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma Treated With Neoadjuvant Chemotherapy: a Turkish Oncology Group Study

    Research Square, 2021

    DOI 10.21203/rs.3.rs-884239/v1 Open-access full textSource: ORCID

  49. Pulmonary langerhans cell histiocytosis: Can it originate from chest trauma?

    Archives of Trauma Research, 2021

    DOI 10.4103/atr.atr_85_20 Open-access full textSource: OpenAlex

  50. Evaluation of the Relationship between Antioxidant Gene Polymorphisms (Endothelial Nitric Oxide Synthase, Myeloperoxidase, Uncoupling Protein 2) and Breast Cancer

    Eurasian Journal of Medicine and Oncology, 2020

    DOI 10.14744/ejmo.2020.99886 1 citation (OpenAlex) Open-access full textSource: OpenAlex